Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
about
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysisObesity and cancer: mechanistic insights from transdisciplinary studiesLifestyle and dietary factors in the prevention of lethal prostate cancerClinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging.PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES.Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004).The interaction of body mass index and race in predicting biochemical failure after radical prostatectomy.Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.Predictive value of digital rectal examination for prostate cancer detection is modified by obesityThe diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer.Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study.Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting.Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients.The association between BMI and plasma cytokine levels in patients with acute lung injury.Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination SurveyThe influence of hepatic function on prostate cancer outcomes after radical prostatectomy.Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African AmericansEnergetics in colorectal and prostate cancer.Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study.Serum prostate-specific antigen levels and type of work in tire manufacturing workers.Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.Association of serum sex steroid hormone hemodilution and body mass index among healthy postmenopausal women.Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia.DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study.Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.Obesity is a significant risk factor for prostate cancer at the time of biopsy.Serum prostate specific antigen changes in cynomolgus monkeys (Macaca fascicularis) on a high sugar high fat diet.Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer.A high-fat diet containing lard accelerates prostate cancer progression and reduces survival rate in mice: possible contribution of adipose tissue-derived cytokinesHigher body mass index increases the risk for biopsy-mediated detection of prostate cancer in Chinese men.Prostate kallikrein markers in diagnosis, risk stratification and prognosis.Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, CanadaAssociation of obesity and smoking with PSA and PSA velocity in men with prostate cancer.Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH databaseIndividual- and neighborhood-level education influences the effect of obesity on prostate cancer treatment failure after prostatectomy.Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer.
P2860
Q24625223-15F87AE8-CDF3-40AE-8210-7941F407B7A7Q26786829-0288D4F3-01D8-449E-A81A-527EA4E0EB02Q27025735-0DDD7DF8-D33B-4818-9938-346319B28B31Q30843223-F3788F97-9078-4B45-9E96-D6BB0C01EFA7Q33511139-2EBF8635-E075-43F1-8006-4900A33C1F7BQ33560705-FA4B7EA5-4FDE-4788-BCD0-C0BC806C53C8Q33591357-50A152B0-A95D-4EDD-B852-DFF5A479C286Q33655802-8F3EB4CF-A662-4A2C-9287-468E75E8A3E4Q33717385-BFACB763-DC98-476D-9159-311E05853E52Q33728225-EB9B865F-F56A-4762-99F7-7F69B956DF31Q33778985-301FD776-82BE-49E7-8AFF-2383AAF359ABQ33856172-BB55CC8D-B7FF-4A0F-B6E9-148F7A4F06B1Q33901167-52847572-417E-4F6C-9C2C-A93BBDE9FC81Q34027912-274D25B2-4CAD-4323-81D7-8436575C90EBQ34128835-2AED9B50-E06F-4AD8-89AC-E4697904180FQ34130717-3E901FB0-7FBE-4314-B2D5-2DE8A3781FF3Q34131771-EC437AC5-1576-4F2D-BAC5-40A07EA224B8Q34162770-8B32460A-3D0A-45AC-8EE6-7A1FD5B08A32Q34288514-3448CB26-7399-4108-8AA7-C64A967E0EE6Q34300064-126C1C1B-D787-4BA0-BABE-2332BBF8B88AQ34315768-5B0445FE-2843-4F3B-BED6-67241E5B9DE1Q34325137-18360D50-A012-4184-9A15-F14D758FEB6EQ34641998-39427AAF-3910-464A-B339-B2B5A7ED3B77Q34787613-B77F8587-CA65-407C-9D61-868E1C4AB971Q34845451-D269E13D-51B9-4CE2-93AE-2FD846388D6BQ34958461-53D820E7-359D-449D-AF3E-5243F6939F1AQ35070021-A78E649F-89A4-4BDB-A2D7-A8EE619535AAQ35135067-EE184E69-DC2A-45C3-BFE0-E6501549DBE4Q35186197-D16FE088-DC6E-46E4-A442-C946822819A0Q35231117-ED30D555-BF27-4C20-9BDF-27198F059B15Q35250119-775FD113-506C-4D22-8CFE-DE5BBF1733ADQ35292828-8DFD48E6-5294-4E66-8789-2823C83AC618Q35585932-5342EEED-3194-4AAC-A5F0-F1C6EBCE46B1Q35599285-640F7F1C-705E-4447-A5D8-FA13A5E70F0DQ35683035-2F3E8E4F-C86D-4C2B-A1D8-41F3A0B6311FQ35781093-C5FBAA0B-B86E-4DC5-AF0A-F2E9FCA66441Q35924445-B5A72455-6EE8-4E12-A234-31511D21EE15Q35931460-09D3357B-87CB-465F-803A-D1FD11118DD5Q35968041-9CD1BB14-97F1-4DF9-B78E-E376F05AC067Q35985620-EE4A8ADA-95CA-4440-8071-4E531F3069E0
P2860
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@ast
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@en
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@nl
type
label
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@ast
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@en
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@nl
prefLabel
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@ast
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@en
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@nl
P2093
P50
P356
P1476
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
@en
P2093
Carmen Rodriguez
Christopher J Kane
Christopher L Amling
Joseph C Presti
Judd W Moul
Lionel L Bañez
Robin T Vollmer
Stephen J Freedland
William J Aronson
P304
P356
10.1001/JAMA.298.19.2275
P407
P577
2007-11-01T00:00:00Z